In this study, low-value PSA screening for prostate cancer increased from 2016 to 2018 and was associated with unnecessary expenditures due to avoidable care cascades, despite multiple guidelines recommending against its routine use in men aged 70 years and older. The gene discussed is KLK3; the disease is prostate carcinoma.